Neomycin And Polymyxin B Sulfates
Xgen Pharmaceuticals Djb, Inc.
Human Prescription Drug
NDC 39822-1220Neomycin And Polymyxin B Sulfates is a human prescription drug labeled by 'Xgen Pharmaceuticals Djb, Inc.'. National Drug Code (NDC) number for Neomycin And Polymyxin B Sulfates is 39822-1220. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Neomycin And Polymyxin B Sulfates drug includes Neomycin Sulfate - 40 mg/mL Polymyxin B Sulfate - 200000 [USP'U]/mL . The currest status of Neomycin And Polymyxin B Sulfates drug is Active.
Drug Information:
| Drug NDC: | 39822-1220 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Neomycin And Polymyxin B Sulfates |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Neomycin And Polymyxin B Sulfates |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Xgen Pharmaceuticals Djb, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Solution |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | NEOMYCIN SULFATE - 40 mg/mL
POLYMYXIN B SULFATE - 200000 [USP'U]/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | IRRIGATION
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | ANDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 31 Jan, 2006 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 23 Jan, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | ANDA065108 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | XGen Pharmaceuticals DJB, Inc.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 314124
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 19371312D4
057Y626693
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class: | Aminoglycoside Antibacterial [EPC]
Aminoglycosides [CS]
Polymyxin-class Antibacterial [EPC]
Polymyxins [CS]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 39822-1220-1 | 1 VIAL, GLASS in 1 CARTON (39822-1220-1) / 20 mL in 1 VIAL, GLASS | 31 Jan, 2006 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Product Elements:
Neomycin and polymyxin b sulfates neomycin and polymyxin b sulfates nitrogen sulfuric acid water neomycin sulfate neomycin polymyxin b sulfate polymyxin b neomycin and polymyxin b sulfates neomycin and polymyxin b sulfates nitrogen sulfuric acid water methylparaben neomycin sulfate neomycin polymyxin b sulfate polymyxin b
Indications and Usage:
Indications and usage neomycin and polymyxin b sulfates solution for irrigation is indicated for short-term use (up to 10 days) as a continuous irrigant or rinse in the urinary bladder of abacteriuric patients to help prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters. since organisms gain entrance to the bladder by way of, through, and around the catheter, significant bacteriuria is induced by bacterial multiplication in the bladder urine, in the mucoid film often present between catheter and urethra, and in other sites. urinary tract infection may result from the repeated presence in the urine of large numbers of pathogenic bacteria. the use of closed systems with indwelling catheters has been shown to reduce the risk of infection. a three-way closed catheter system with constant neomycin-polymyxin b bladder rinse is indicated to prevent the development of infection while using indwelling catheters. if uropathogens are isolated, they
Read more...should be identified and tested for susceptibility so that appropriate antimicrobial therapy for systemic use can be initiated.
Warnings:
Warnings prophylactic bladder care with neomycin and polymyxin b sulfates solution for irrigation should not be given where there is a possibility of systemic absorption. neomycin and polymyxin b sulfates solution should not be used for irrigation other than for the urinary bladder. systemic absorption after topical application of neomycin to open wounds, burns, and granulating surfaces is significant and serum concentrations comparable to and often higher than those attained following oral and parenteral therapy have been reported. absorption of neomycin from the denuded bladder surface has been reported. however, the likelihood of toxicity following topical irrigation of the intact urinary bladder with neomycin and polymyxin b sulfates solution for irrigation is low since no appreciable amounts of these antibiotics enter the systemic circulation by this route if irrigation does not exceed 10 days. neomycin and polymyxin b sulfates solution for irrigation is intended for continuous pr
Read more...ophylactic irrigation of the lumen of the intact urinary bladder of patients with indwelling catheters. patients should be under constant supervision by a physician. irrigation should be avoided in patients with defects in the bladder mucosa or bladder wall, such as vesical rupture, or in association with operative procedures on the bladder wall, because of the risk of toxicity due to systemic absorption following diffusion into absorptive tissues and spaces. when absorbed, neomycin and polymyxin b are nephrotoxic antibiotics, and the nephrotoxic potentials are additive. in addition, both antibiotics, when absorbed, are neurotoxins: neomycin can destroy fibers of the acoustic nerve causing permanent bilateral deafness; neomycin and polymyxin b are additive in their neuromuscular blocking effects, not only in terms of potency and duration, but also in terms of characteristics of the blocks produced. aminoglycosides, when absorbed, can cause fetal harm when administered to a pregnant woman. aminoglycoside antibiotics cross the placenta and there have been several reports of total, irreversible, bilateral, congenital deafness in children whose mothers received streptomycin during pregnancy. although serious side effects have not been reported in the treatment of pregnant women with other aminoglycosides, the potential for harm exists. if neomycin and polymyxin b sulfates solution for irrigation is used during pregnancy, the patient should be apprised of the potential hazard to the fetus (see precautions ).
General Precautions:
General ototoxicity, nephrotoxicity, and neuromuscular blockade may occur if neomycin and polymyxin b sulfates solution for irrigation ingredients are systemically absorbed (see warnings ). absorption of neomycin from the denuded bladder surface has been reported. patients with impaired renal function, infants, dehydrated patients, elderly patients, and patients receiving high doses of prolonged treatment are especially at risk for the development of toxicity. irrigation of the bladder with neomycin and polymyxin b sulfates solution for irrigation may result in overgrowth of nonsusceptible organisms, including fungi. appropriate measures should be taken if this occurs. the safety and effectiveness of the preparation for use in the care of patients with recent lower urinary tract surgery have not been established. urine specimens should be collected during prophylactic bladder care for urinalysis, culture, and susceptibility testing. positive cultures suggest the presence or organisms w
Read more...hich are resistant to the bladder rinse antibiotics.
Dosage and Administration:
Dosage and administration this preparation is specifically designed for use with âthree-way catheters or with other catheter systems permitting continuous irrigation of the urinary bladder. the usual irrigation dose is one 1-ml ampul a day for up to 10 days. using strict aseptic techniques, the contents of 1-ml ampul of neomycin and polymyxin b sulfates solution for irrigation should be added to a 1,000-ml container of isotonic saline solution. this container should then be connected to the inflow lumen of the âthree-wayâ catheter which has been inserted with full aseptic precautions; use of a sterile lubricant is recommended during insertion of the catheter. the outflow lumen should be connected, via a sterile disposable plastic tube, to a disposable plastic collection bag. stringent procedures, such as taping the inflow and outflow junction at the catheter, should be observed when necessary to insure the junctional integrity of the system. for most patients, the inflow
Read more... rate of the 1,000-ml saline solution of neomycin and polymyxin b should be adjusted to a slow drip to deliver about 1,000 ml every 24 hours. if the patientâs urine output exceeds 2 liters per day, it is recommended that the inflow rate be adjusted to deliver 2,000 ml of the solution in a 24-hour period. it is important that the rinse of the bladder be continuous ; the inflow or rinse solution should not be interrupted for more than a few minutes. preparation of the irrigation solution should be performed with strict aseptic techniques. the prepared solution should be stored at 4°c, and should be used within 48 hours following preparation to reduce the risk of contamination with resistant microorganisms.
Contraindications:
Contraindications hypersensitivity to neomycin, the polymyxins, or any ingredient in the solution is a contraindication to its use. a history of hypersensitivity or serious toxic reaction to an aminoglycoside may also contraindicate the use of any other aminoglycoside because of the known cross-sensitivity of patients to drugs of this class.
Adverse Reactions:
Adverse reactions neomycin occasionally causes skin sensitization when applied topically; however, topical application to mucus membranes rarely results in local or systemic hypersensitivity reactions. irritation of the urinary bladder mucosa has been reported. signs of ototoxicity and nephrotoxicity have been reported following parenteral use of drugs and following the oral and topical use of neomycin (see warnings ). to report suspected adverse reactions, contact xgen pharmaceuticals djb, inc. at 1-866-390-4411 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.
Use in Pregnancy:
Pregnancy teratogenic effects pregnancy category d. see warnings section.
Pediatric Use:
Pediatric use safety and effectiveness in pediatric patients have not been established.
Description:
Description neomycin and polymyxin b sulfates solution for irrigation is a concentrated sterile antibiotic solution to be diluted for urinary bladder irrigation. each ml contains neomycin sulfate equivalent to 40 mg neomycin base, 200,000 units polymyxin b sulfate, and water for injection, inactive ingredient: sulfuric acid. the 20-ml multiple dose vial contains, in addition to the above, 1 mg methylparaben (0.1%) added as a preservative. neomycin sulfate, an antibiotic of the aminoglycoside group, is the sulfate salt of neomycin b and c produced by streptomyces fradiae. it has a potency equivalent to not less than 600 mcg of neomycin per mg. the structural formulae are: polymyxin b sulfate, a polypeptide antibiotic, is the sulfate salt of polymyxin b 1 and b 2 produced by the growth of bacillus polymyxa. it has a potency of not less than 6,000 polymyxin b units per mg. the structural formulae are: c:\documents and settings\junem.x-gen.000\desktop\01.jpg j:\qa-ra\regulatory affairs\june\02.jpg
Clinical Pharmacology:
Clinical pharmacology after prophylactic irrigation of the intact urinary bladder, neomycin and polymyxin b are absorbed in clinically insignificant quantities. a neomycin serum level of 0.1 mcg/ml was observed in three of 33 patients receiving the rinse solution. this level is well below that which has been associated with neomycin-induced toxicity. when used topically, polymyxin b sulfate and neomycin are rarely irritating. microbiology the prepared neomycin and polymyxin b sulfates solution for irrigation is bactericidal. the aminoglycosides act by inhibiting normal protein synthesis in susceptible microorganisms. polymyxins increase the permeability of bacterial cell wall membranes. the solution is active in vitro against: escherichia coli staphylococcus aureus haemophilus influenzae klebsiella and enterobacter species neisseria species, and pseudomonas aeruginosa it is not active in vitro against serratia marcescens and streptococci. bacterial resistance may develop following the
Read more...use of the antibiotics in the catheter-rinse solution.
How Supplied:
How supplied neomycin and polymyxin b sulfates solution for irrigation are supplied as 1 ml/ampul (ndc 39822-1201-1) in boxes of 10 (ndc 39822-1201-2), 50 (ndc 39822-1201-5) and 20 ml multiple dose vial in single vial cartons (ndc 39822-1220-1). store at 2° to 8°c (36° to 46°f). manufactured for: xgen pharmaceuticals djb, inc. big flats, ny 14814 revised: december 2020 np-pi-04 xg djb rx only
Package Label Principal Display Panel:
Package label.principal display panel ndc 39822-1201-1 neomycin and polymyxin b sulfates solution for irrigation, usp sterile 1 ml xgen pharmaceuticals djb, inc. for irrigation use only not for injection ndc 39822-1201-2 neomycin and polymyxin b sulfates solution for irrigation, usp sterile 10 ampul carton xgen pharmaceuticals djb, inc. for irrigation use only not for injection ndc 39822-1201-5 neomycin and polymyxin b sulfates solution for irrigation, usp sterile 50 ampul carton xgen pharmaceuticals djb, inc. for irrigation use only not for injection ndc 39822-1220-1 neomycin and polymyxin b sulfates solution for irrigation, usp sterile 20 ml xgen pharmaceuticals djb, inc. for irrigation use only not for injection ndc 39822-1220-1 neomycin and polymyxin b sulfates solution for irrigation, usp sterile single vial carton xgen pharmaceuticals djb, inc. for irrigation use only not for injection ampul label 10 amp carton 50 amp carton vial label vial carton